论文部分内容阅读
Healthy volunteers were randomly divided into TFH group(22 subjects) and placebo control group (20 subjects). We used double-blind method. The cardiac performance and hemodynamics of the subjects before and after administration of TFH or placebo were determined by Admittance and STI methods, Oral TFH in a dose of 10 mg could significantly decrease the PEP/LVET, ICT/LVET and ICT of the mormal subjects(P<0.05). Oral TFH could increase SV(P<0.05). CO, CI, SWI, CWI and LI also tended to increase. Oral TFH also markedly reduced TPR (P<0.05) and increasedc (P<0.05). After administration of TFH, HR and HP did not significantly change(P>0.05). After administration of placebo, the parameters observed did not significantly change(P>0.05). The above results show that TFH can strengthen myocardial contractility and pump function of the heart, reduce total peripheral vascular resistance and increase vascular clasticity in normal subjects.
Healthy volunteers were randomly divided into TFH group(22 subjects) and placebo control group (20 subjects). We used double-blind method. The cardiac performance and hemodynamics of the subjects before and after administration of TFH or placebo were determined by Admittance and STI Methods, Oral TFH in a dose of 10 mg could significantly decrease the PEP/LVET, ICT/LVET and ICT of the mormal subjects (P<0.05). Oral TFH could increase SV (P<0.05). CO, CI, SWI, CWI and LI also tended to increase. Oral TFH also markedly reduced TPR (P<0.05) and increasedc (P<0.05). After administration of TFH, HR and HP did not change significantly (P>0.05). After administration of placebo, The above results did not significantly change(P>0.05). The above results show that TFH can strengthen the myocardial contractility and pump function of the heart, reduce total peripheral vascular resistance and increase vascular clasticity in normal subjects.